HOT off the ECTRIMS Press: Genzyme’s Campath (alemtuzumab) Treatment Helps MS Patients at 5 Years

Genzyme Corp.’s Campath cut the risk of relapse in multiple sclerosis patients by 69 percent compared with Merck KGaA’s Rebif after five years, according to a study. [...]

• Caroline says: Alemtuzumab probably won't be a blockbuster drug, according to this article. Safety is an issue, but once-yearly dosing via infusion sounds good. Better than a pill every day?
   

• Related Links:
• http://www.bloomberg.com/news/2010-10-14/genzyme-s-campath-helps-multiple-sclero…

• Update on alemtuzumab (Campath) in RRMS

  Alemtuzumab (Campath) is an experimental new drug treatment for people with relapsing remitting multiple sclerosis (MS). Other names: Campath In development for: Relapsing remitting multiple sclerosis (MS) [...]

  • Caroline says: As MS News Today reported in June 2010, alemtuzumab (Campath) received fast track status from the FDA for an RRMS indication. Alemtuzumab is currently approved for certain types of leukemia. I am posting two links relevant to this topic: the first gives more general business/stock/market information. The second link gives side effects/dosing/clinical study information. Happy reading!
     
  • Related Links:
  • http://www.moneycontrol.com/news/world-news/multiple-sclerosis-drugwild-cardgenz…
  • http://www.mstrust.org.uk/research/drugsindevelopment/alemtuzumab.jsp…
  
  

  • Genzyme’s Alemtuzumab Granted Fast Track Status by FDA for RRMS

    CAMBRIDGE, Mass., Jun 14, 2010 (BUSINESS WIRE) — Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by [...]

    • Caroline says: Hot damn. Alemtuzumab has been granted fast-track status by the FDA, which means that the drug is eligible for expedited FDA review (read: it will be on the market sooner). Trials currently underway for alemtuzumab and MS are comparing it against Rebif.
       
    • Related Links:
    • http://www.news-medical.net/news/20100615/FDA-grants-Fast-Track-status-for-Genzy…
    
    

    • Hot off the ECTRIMS Press…Alemtuzumab Shows Lasting Benefits in RRMS

      (RTTNews) -  Friday, biotechnology company Genzyme Corp. said that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate [...]

      • Caroline says: The possibility of alemtuzumab (Campath) being FDA approved for MS should excite some of you b-cell MS'ers. Genzyme says that four-year follow-up data from its completed Phase 2 MStrial show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.